Charles River Laboratories Stock Rallies 11.0% Amid Improved Earnings Outlook

CRL shares jumped as much as 11% on August 5, 2026, touching a fresh 52-week high near $260, after the contract research organization beat second-quarter estimates and raised its full-year guidance.

The move matters because it is the clearest sign yet that the multi-year slump in biotech research spending, which has weighed on preclinical CROs since 2023, may be turning. Charles River's Discovery and Safety Assessment segment posted its first organic revenue growth since the third quarter of 2023.

Adjusted EPS came in at $3.02 versus a $2.74 consensus, and revenue reached roughly $1.0 billion against expectations near $976 million. Net bookings in Discovery and Safety Assessment rose 12.6% sequentially to $701 million, pushing the book-to-bill ratio to 1.19x, its highest level in nearly four years. GAAP results still showed a net loss of $1.5 million, or $0.03 per share, driven by a $63.7 million charge tied to the divestiture of the CDMO and Cell Solutions businesses, not by underlying operating weakness.

Management raised full-year adjusted EPS guidance to $11.15-$11.45 and lifted revenue guidance to $3.879-$3.920 billion. The open question is whether the bookings rebound reflects a durable recovery in biopharma R&D budgets or a shorter-term order catch-up, which could shape how peer CROs trade through the rest of 2026.

Related Stocks

• CRL